Odyssey Therapeutics, Inc. (ODTX) is a Healthcare stock trading at $24.67 (as of 2026-08-20), with a market capitalization of $1.19B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Understand Odyssey Therapeutics, Inc.: how it makes money
Odyssey Therapeutics is a healthcare pharmaceutical products company. The provided facts do not specify what specific products it sells or the exact revenue model it uses to make money.
The provided facts do not include product lines, segment reporting, or operating KPIs, so the profit-model driver cannot be identified from this dataset.
Business quality (Weak): Data coverage is too limited here (no business description, no segments, no operating KPIs). Only a very negative operating margin is provided for the latest period.
Bull case
Large operating loss is explicitly disclosed: For the quarter ended 2025-03-31, the company reports an operating_margin_pct of -2041.7%, which highlights how strongly costs outweigh operating results in the latest provided period.
Bear case
Profitability appears deeply negative in the latest provided quarter: The company reports operating_margin_pct of -2041.7% for the quarter ended 2025-03-31, indicating significant operating losses relative to revenue.
Revenue level is shown as 0.0B in the provided facts: The provided financials show revenue_b as 0.0B for the quarter ended 2025-03-31, and no segment detail is included to explain the revenue source or trajectory.
Missing operating metrics and segments limit visibility: No operational KPIs or official reportable segments are included in the provided facts, which makes it harder for investors to track the underlying drivers of performance.
Valuation — source: SEC EDGAR (first-party)
Price
$24.67
Market Cap
$1.19B
Price / Book
2.81
Price / Sales
1236.29
FCF Yield
-19.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$2.98M
Net Margin
-4994.9%
Revenue Growth (YoY)
-100.0%
EPS Growth (YoY)
-94.1%
FCF Growth (YoY)
2.8%
Financial Health — source: SEC EDGAR
Altman Z-Score
-3.19 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)
21.6
Industry P/E (Pharmaceutical Products)
17.2
Company
Sector
Healthcare
Industry
Pharmaceutical Products
Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)